RxDoctor Payments Data

Christina Cohee, NP

Gerontology · Crawfordsville, INNPI 1124645536

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $879 and has fallen 70.8% since, to $256 in 2025.

$2,445in general payments, 2019–2025

Across 120 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$530
  • Amgen$455
  • Boehringer Ingelheim$311
  • E.r. Squibb & Sons, L.L.C.$150
  • AstraZeneca$133
  • Merck$131
  • plus $736 from 14 others

What the payments were for

  • Food & beverage$2,445100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,445 in reported general payments places this provider in the 85th percentile of 230 gerontology providers in Indiana.

See all gerontology providers in Indiana

Medicare billing

Part B allowed, 2024
$37,073
Medicare patients
224
Services billed
1,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$49,857
JardianceEmpagliflozin33$25,658
EntrestoSacubitril/Valsartan26$17,266
Repatha SureclickEvolocumab19$12,591
XareltoRivaroxaban16$9,085
BrilintaTicagrelor11$4,867
Ranolazine ErRanolazine54$3,840
ClopidogrelClopidogrel Bisulfate195$1,496
Amiodarone Hcl20$1,218
Torsemide39$924
Colchicine13$903
Metoprolol Succinate132$811
Rosuvastatin Calcium105$723
Isosorbide Mononitrate ErIsosorbide Mononitrate84$542
Atorvastatin Calcium118$358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$49,85768 claims
Boehringer IngelheimJardiance$311$25,65833 claims
NovartisEntresto$530$17,26626 claims
Johnson & JohnsonXarelto$40$9,08516 claims
AstraZenecaBrilinta$133$4,86711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 230 gerontology providers in Indiana.

Other gerontology in Crawfordsville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →